vs
Side-by-side financial comparison of Farmland Partners Inc. (FPI) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Farmland Partners Inc. is the larger business by last-quarter revenue ($20.7M vs $20.6M, roughly 1.0× Entrada Therapeutics, Inc.). Farmland Partners Inc. runs the higher net margin — 103.4% vs -84.4%, a 187.8% gap on every dollar of revenue. On growth, Farmland Partners Inc. posted the faster year-over-year revenue change (-3.5% vs -65.2%). Over the past eight quarters, Farmland Partners Inc.'s revenue compounded faster (31.4% CAGR vs 6.4%).
Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
FPI vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.7M | $20.6M |
| Net Profit | $21.4M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | — | -106.0% |
| Net Margin | 103.4% | -84.4% |
| Revenue YoY | -3.5% | -65.2% |
| Net Profit YoY | -63.5% | -173.8% |
| EPS (diluted) | $0.44 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.7M | — | ||
| Q3 25 | $11.3M | — | ||
| Q2 25 | $10.0M | — | ||
| Q1 25 | $10.3M | $20.6M | ||
| Q4 24 | $21.5M | $37.4M | ||
| Q3 24 | $13.3M | $19.6M | ||
| Q2 24 | $11.4M | $94.7M | ||
| Q1 24 | $12.0M | $59.1M |
| Q4 25 | $21.4M | — | ||
| Q3 25 | $483.0K | — | ||
| Q2 25 | $7.6M | — | ||
| Q1 25 | $2.0M | $-17.3M | ||
| Q4 24 | $58.7M | $1.1M | ||
| Q3 24 | $1.8M | $-14.0M | ||
| Q2 24 | $-2.0M | $55.0M | ||
| Q1 24 | $1.4M | $23.5M |
| Q4 25 | — | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 20.6% | -106.0% | ||
| Q4 24 | — | -15.7% | ||
| Q3 24 | 13.9% | -110.7% | ||
| Q2 24 | -17.9% | 56.4% | ||
| Q1 24 | 11.9% | 35.7% |
| Q4 25 | 103.4% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 76.3% | — | ||
| Q1 25 | 19.9% | -84.4% | ||
| Q4 24 | 273.6% | 3.0% | ||
| Q3 24 | 13.5% | -71.7% | ||
| Q2 24 | -17.5% | 58.1% | ||
| Q1 24 | 11.5% | 39.7% |
| Q4 25 | $0.44 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.03 | $-0.42 | ||
| Q4 24 | $1.09 | $-0.20 | ||
| Q3 24 | $0.02 | $-0.35 | ||
| Q2 24 | $-0.06 | $1.55 | ||
| Q1 24 | $0.01 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $67.8M |
| Total DebtLower is stronger | $161.6M | — |
| Stockholders' EquityBook value | $467.4M | $417.3M |
| Total Assets | $719.1M | $486.5M |
| Debt / EquityLower = less leverage | 0.35× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $67.8M | ||
| Q4 24 | — | $101.2M | ||
| Q3 24 | — | $78.0M | ||
| Q2 24 | — | $185.3M | ||
| Q1 24 | — | $68.4M |
| Q4 25 | $161.6M | — | ||
| Q3 25 | $170.4M | — | ||
| Q2 25 | $193.4M | — | ||
| Q1 25 | $202.6M | — | ||
| Q4 24 | $204.6M | — | ||
| Q3 24 | $394.0M | — | ||
| Q2 24 | $393.0M | — | ||
| Q1 24 | $383.0M | — |
| Q4 25 | $467.4M | — | ||
| Q3 25 | $457.3M | — | ||
| Q2 25 | $473.5M | — | ||
| Q1 25 | $492.2M | $417.3M | ||
| Q4 24 | $494.6M | $428.7M | ||
| Q3 24 | $519.4M | $422.4M | ||
| Q2 24 | $521.5M | $429.9M | ||
| Q1 24 | $526.7M | $269.4M |
| Q4 25 | $719.1M | — | ||
| Q3 25 | $738.5M | — | ||
| Q2 25 | $776.7M | — | ||
| Q1 25 | $810.5M | $486.5M | ||
| Q4 24 | $869.6M | $526.3M | ||
| Q3 24 | $1.0B | $554.6M | ||
| Q2 24 | $1.0B | $582.0M | ||
| Q1 24 | $1.0B | $510.8M |
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.4M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | 0.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.4M | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-2.2M | — | ||
| Q1 25 | $6.4M | $-38.5M | ||
| Q4 24 | $16.1M | $-31.6M | ||
| Q3 24 | $-4.3M | $-24.3M | ||
| Q2 24 | $-6.1M | $39.8M | ||
| Q1 24 | $11.9M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | 0.81× | — | ||
| Q3 25 | -4.04× | — | ||
| Q2 25 | -0.29× | — | ||
| Q1 25 | 3.12× | — | ||
| Q4 24 | 0.27× | -27.94× | ||
| Q3 24 | -2.39× | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | 8.66× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
